NASDAQ:EQ
Equillium Inc. Stock News
$1.54
+0 (+0%)
At Close: May 16, 2024
Equillium's Itolizumab Shows Encouraging Safety, Tolerability Profile In Systemic Lupus Erythematosus Study
07:44am, Wednesday, 31'st Mar 2021
Equillium Inc (NASDAQ: EQ) has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus (SLE). Data from the
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
04:01pm, Tuesday, 30'th Mar 2021
Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
04:05pm, Wednesday, 24'th Mar 2021
Cash runway into the second half of 2023
Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial reduction in baseline corticosteroid use
Equillium Announces the Appointment of Katherine Xu to the Board of Directors
08:00am, Tuesday, 09'th Feb 2021
LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, tod
Equillium Announces Closing of $30 Million Registered Direct Offering
05:36pm, Friday, 05'th Feb 2021
LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, tod
Equillium Raises $30M Via Equity, Shares Rally
10:53am, Thursday, 04'th Feb 2021
Equillium Inc (NASDAQ: EQ) has entered into a securities purchase agreement with Decheng Capital to purchase around 4.3 million units from Equillium at $7 per unit, equivalent to gross proceeds of $30
Equillium Announces Pricing of $30 Million Registered Direct Offering
08:00am, Thursday, 04'th Feb 2021
LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, tod
LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, tod
Studies further support itolizumab's potential as treatment for aGVHD patients Studies further support itolizumab's potential as treatment for aGVHD patients
Equillium (EQ) Stalls Initiation of Phase III Study on COVID-19
10:24am, Thursday, 26'th Nov 2020
Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.
Equillium's stock tumbles after decision to not initiate late-stage trial of COVID-19 treatment
08:46am, Wednesday, 25'th Nov 2020
Shares of Equillium Inc. tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 trial its itolizumab for the treatment of hospitalized
Equillium Provides Itolizumab COVID-19 Program Update
08:00am, Wednesday, 25'th Nov 2020
Analyst Day scheduled for December 4, 2020 Analyst Day scheduled for December 4, 2020
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
04:05pm, Tuesday, 10'th Nov 2020
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
Equillium to Present at Investor Conferences in November 2020
08:35am, Tuesday, 10'th Nov 2020
LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to
